Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 57

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 57
---
.

41

PEO and Average Non-PEO NEO Compensation Actually Paid
Versus TSR Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Earnings The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Net Earnings during the four most recently completed fiscal years. PEO and Average Non-PEO NEO Compensation Actually Paid
Versus Net Earnings Net Earnings included in the preceding chart is calculated in accordance with GAAP (Generally Accepted Accounting Principles). During 2021, 2022, 2023 and 2024, the Company recorded amortization expenses for intangible assets of $30.0 million, $82.6 million, $82.4 million and $78.0 million, respectively. The 42

level of amortization of intangible assets increased during 2021 and increased further in 2022 primarily due to the amortization of definitive-lived intangible assets acquired in the US WorldMeds and Adamas acquisitions. Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Gross Product Sales The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Gross Product Sales during the four most recently completed fiscal years. PEO and Average Non-PEO NEO Compensation Actually Paid
Versus Gross Product Sales Tabular List of Most Important Financial Performance Measures The following table presents the financial performance measures that the Company considers the most important in linking Compensation Actually Paid to our PEO and Non-PEO NEOs for 2023 to Company performance. The measures in this table are not ranked.

| ​ | ​ | Gross Product Sales | ​ | ​ |
| ​ | ​ | Operating Earnings  | ​ | ​ |

POLICIES AND PRACTICES RELATED TO THE TIMING OF GRANTS OF CERTAIN EQUITY AWARDS At a regularly scheduled annual meeting of the Company’s Board of Directors and Compensation Committee held in late February or early March of each year, it is the Board’s and Compensation Committee’s long-standing practice to review the Company’s results for the most recently completed fiscal year, review the company’s financial plan and strategy for the upcoming fiscal year. At these meetings the Compensation Committee also review the performance of the Company’s executive officers with the Chief Executive Officer and based on those reviews, approves the grant of cash bonuses and equity awards